Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Kalafatis (Stockholm, Sweden), L. Carlson (Stockholm, Sweden), J. Gao (Stockholm, Sweden), C. Li (Stockholm, Sweden), I. Pesonen (Stockholm, Sweden), C. Sköld (Stockholm, Sweden). Cluster analysis and survival in patients with Idiopathic pulmonary fibrosis. 1840

Member's Comments

No comment yet.

Related content which might interest you: Clinical characteristics and survival in patients with idiopathic pulmonary fibrosis with and without associated emphysema Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study Source: Eur Respir J 2012; 40: 101-109 Year: 2012 Idiopathic pulmonary fibrosis: Gender differences in survival and functional decline. A retrospective study Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Survival predictors in a cohort of patients with idiopathic pulmonary fibrosis biopsy-proven Source: Annual Congress 2012 - Diffuse parenchymal lung disease IV Year: 2012 Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Idiopathic pulmonary upper lobe fibrosis shows distinct features and poor prognosis compared to idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Warfarin and survival in people with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2007; 30: Suppl. 51, 246s Year: 2007 Idiopathic pulmonary fibrosis: Relationship between patient survival and distance-saturation product Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Genetic predictors of idiopathic pulmonary fibrosis (IPF) prognosis Source: Eur Respir J 2006; 28: Suppl. 50, 830s Year: 2006 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Biopsy documented idiopathic interstitial pneumonias - Analysis of diagnostic yield, survival and mortality over 9 years Source: Annual Congress 2013 –Interventional procedures for diagnosis of diffuse lung diseases and peripheral pulmonary lesions Year: 2013 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Median survival in unselected patients with idiopathic pulmonary fibrosis in the United Kingdom Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Real life experience with nintedanib in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Idiopathic pulmonary fibrosis (IPF): the patient journey Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020 Item generation for a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF): Application of consensus methods Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Onset of symptoms in idiopathic pulmonary fibrosis: A case-control study Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016